Table 2.
Associations Between Select Patient Characteristics and Mobility Test Completion Times
| Patient Characteristic | Timed-Up-And-Go | Five-Times Sit-To-Stand | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Median | Mean | SD | Sig. | Effect sizea | N | Median | Mean | SD | Sig. | Effect sizea | ||
| Sex | Male | 37 | 10.0 | 12.5 | 6.5 | 0.270 | 0.14 | 37 | 12.0 | 13.7 | 5.9 | 0.494 | 0.09 |
| Female | 25 | 11.0 | 13.6 | 7.2 | 25 | 13.0 | 17.4 | 14.2 | |||||
| Karnofsky performance status (KPS) | Poor (≤80) | 14 | 17.5* | 19.1 | 8.1 | <0.001 | 0.52 | 14 | 17.5* | 20.9 | 12.4 | 0.005 | 0.36 |
| Good (≥90) | 48 | 10.0* | 11.2 | 5.2 | 48 | 12.0* | 13.5 | 8.9 | |||||
| Body mass index (BMI) | Normal weight | 22 | 10.0 | 10.9 | 3.3 | 0.167 | 0.03 | 23 | 12.0 | 13.5 | 5.8 | 0.579 | −0.02 |
| Overweight | 14 | 9.0 | 12.6 | 6.3 | 14 | 11.0 | 19.6 | 19.0 | |||||
| Obese | 26 | 12.5 | 14.9 | 8.6 | 25 | 14.0 | 14.2 | 4.6 | |||||
| Patient group | Newly diagnosed | 17 | 11.0 | 14.5 | 7.7 | 0.051 | 0.07 | 18 | 15.0 | 17.1 | 7.0 | 0.032 | 0.08 |
| On treatment | 23 | 12.0 | 13.9 | 7.6 | 22 | 12.0 | 16.3 | 15.1 | |||||
| In follow-up | 22 | 9.0 | 10.8 | 4.5 | 22 | 12.0 | 12.5 | 4.6 | |||||
| Treatment phase | Newly diagnosed | 17 | 11.0 | 14.5 | 7.7 | 0.198 | 0.02 | 18 | 15.0* | 17.1 | 7.0 | 0.024 | 0.09 |
| Recurrence | 17 | 11.0 | 13.4 | 7.9 | 16 | 11.0* | 14.5 | 14.3 | |||||
| Long-term survivors | 28 | 10.0 | 11.8 | 5.4 | 28 | 12.0 | 14.3 | 9.3 | |||||
| WHO tumor grade | I–II | 15 | 10.0 | 10.9 | 3.4 | 0.031 | 0.09 | 15 | 11.0 | 12.3 | 4.2 | 0.155 | 0.03 |
| III | 17 | 10.0 | 11.5 | 5.8 | 16 | 12.0 | 14.4 | 11.4 | |||||
| IV | 29 | 12.0 | 15.0 | 8.1 | 30 | 14.0 | 17.0 | 11.6 | |||||
| Tumor location (lobe) | Frontal | 22 | 10.0 | 10.6 | 3.2 | 0.375 | 0.02 | 23 | 12.0 | 12.3 | 4.0 | 0.401 | 0.02 |
| Temporal | 22 | 11.0 | 14.8 | 9.7 | 21 | 13.0 | 15.5 | 10.4 | |||||
| Parietal/occipital | 11 | 11.0 | 13.5 | 5.9 | 11 | 13.0 | 18.1 | 17.1 | |||||
| Corticosteroid use | Yes | 6 | 14.0* | 13.7 | 3.8 | 0.025 | 0.28 | 6 | 15.5 | 17.3 | 8.2 | 0.058 | 0.24 |
| No | 41 | 10.0* | 12.6 | 7.7 | 41 | 12.0 | 13.8 | 8.3 | |||||
| Anticonvulsant use | Yes | 50 | 11.0 | 13.6 | 7.2 | 0.067 | 0.23 | 49 | 13.0 | 15.9 | 11.1 | 0.306 | 0.13 |
| No | 12 | 9.0 | 10.4 | 3.9 | 13 | 12.0 | 12.3 | 5.2 | |||||
| Tumor recurrence | Yes | 28 | 12.0 | 13.8 | 7.1 | 0.23 | 0.15 | 27 | 13.0 | 16.0 | 13.7 | 0.526 | 0.08 |
| No | 33 | 11.0 | 12.4 | 6.6 | 34 | 12.5 | 14.6 | 6.4 |
Note: all median, mean, and standard deviation (SD) values reported in this table are mobility test completion times measured in seconds. Additionally, 1 patient had a tumor in the corpus callosum and was excluded from the univariate test for tumor location.
*Bolded text indicates statistically significant differences in the median mobility test completion times (ie, P < .025).
aEffect sizes: correlation coefficient (r; sex, Karnofsky Performance Status (KPS), corticosteroid use, anticonvulsant use, and tumor recurrence); eta squared (η 2; Body Mass Index (BMI), patient group, treatment phase, WHO tumor grade, and tumor location (lobe)).